Did You Know...
...In 1790, the cost to obtain a patent was between $4 and $5.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8154713 | Methods of determination of iron deficiency and hemochromatosis New diagnostic parameters or indexes for detection of absolute iron deficiency, latent iron deficiency, functional iron deficiency, or latent functional iron deficiency have been disclosed. The parameters include a RBC size factor, RSf1 defined by the for... | 04/10/2012 |
| 8137975 | Method for a rapid antibody-based analysis of platelet populations A method for identifying a platelet population, preferably a population of immature, reticulated platelets, in a biological sample involves incubating the biological sample for less than 5 minutes with at least one labeled, ligand (e.g., monoclonal antibody) that bi... | 03/20/2012 |
| 8110393 | Method and apparatus for separating and harvesting cells from a whole blood sample The present specification discloses an automated method and apparatus useful for separating and harvesting cells of interest, e.g., mononuclear cells, in a whole blood sample. The method of the invention uses the aspirating/dispensing probe of an automated sample pr... | 02/07/2012 |
| 8063233 | Methods for treating cognitive/attention deficit disorders using tetrahydroindolone analogues and derivatives Methods for treating cognitive/attention deficit disorders in general using tetrahydroindolone derivatives and analogues, particularly tetrahydroindolone derivatives or analogues in which the tetrahydroindolone derivative or analogue is covalently linked to another ... | 11/22/2011 |
| 8030278 | Methods, compositions and articles of manufacture for contributing to the treatment of cancers Methods, compositions and articles of manufacture for contributing to the treatment of cancers, including solid tumors, are disclosed. The methods, compositions and articles of manufacture can utilize an endothelin B agonist (ETB) to enhance the delivery ... | 10/04/2011 |
| 8000940 | Shape parameter for hematology instruments Systems, methods, and computer program products are provided for describing characteristics of a data sample. This description is used to represent the shape of a histogram of the data sample. ... | 08/16/2011 |
| 7977369 | Medical compositions for intravesical treatment of bladder cancer Methods for treating bladder cancer comprising intravesicular administration of a stabilized pharmaceutical formulation comprising 5-(1-aziridinyl)-3-(hydroxymethyl)-2-[(E)-3-hydroxyprop-1-enyl]-1-methyl-1H-indole-4,7-dione (EO9). More specifically, the stabilized p... | 07/12/2011 |
| 7976835 | Methods and compositions for preventing and treating solid tumors Compositions and methods of preventing or treating a breast cancer are disclosed. The composition and method can utilize an endothelin B agonist and a chemotherapeutic agent as active ingredients to treat a solid tumor in mammals, including humans. Alternatively, th... | 07/12/2011 |
| 7855268 | Tolerogizing compositions comprising botulinum toxin type B peptides The present invention provides BoNT/B peptides, BoNT/B peptide compositions, tolerogizing compositions, immune response inducing compositions, as well as methods of determining immunoresistance to botulinum toxin therapy in an individual, methods of treating immunor... | 12/21/2010 |
| 7833535 | Clostridial toxin derivatives and methods for treating pain Agents for treating pain, methods for producing the agents and methods for treating pain by administration to a patient of a therapeutically effective amount of the agent. The agent can include a clostridial neurotoxin, or a component or fragment or derivative there... | 11/16/2010 |
| 7825233 | Optimizing expression of active Botulinum Toxin type E Nucleic acid molecules that comprise modified open reading frames providing increased expression of the encoded active BoNT/E in a heterologous cell, expression constructs and cells comprising such nucleic acid molecules and methods useful for expressing the encodin... | 11/02/2010 |
| 7815917 | Botulinum neurotoxin serotype B activatable Botulinum neurotoxin serotype Bs The specification discloses modified Clostridial toxins comprising a Clostridial toxin substrate cleavage site located within the di-chain loop region; polynucleotide molecules encoding such modified Clostridial toxins comprising a Clostridial toxin substrate cleava... | 10/19/2010 |
| 7780968 | Clostridial toxin derivatives and methods for treating pain Agents for treating pain, methods for producing the agents and methods for treating pain by administration to a patient of a therapeutically effective amount of the agent. The agent can include a clostridial neurotoxin, or a component or fragment or derivative there... | 08/24/2010 |
| 7767718 | Treating pain using selective antagonists of persistent sodium current The present invention provides methods of treating chronic pain in a mammal by administering to the mammal an effective amount of a selective persistent sodium channel antagonist that has at least 20-fold selectivity for persistent sodium current relative to transie... | 08/03/2010 |
| 7763651 | Treating pain using selective antagonists of persistent sodium current The present invention provides methods of treating chronic pain in a mammal by administering to the mammal an effective amount of a selective persistent sodium channel antagonist that has at least 20-fold selectivity for persistent sodium current relative to transie... | 07/27/2010 |
| 7754440 | High-throughput screen for identifying selective persistent sodium channels channel blockers A method for identifying a selective persistent Na+ channel blocker by measuring the ability of the blocker to reduce or inhibit a persistent Na+ current to a greater degree than a transient Na+ current. Aspects of the present method... | 07/13/2010 |
| 7749759 | Cell compositions useful for cell-based FRET assays for clostridial toxins The present invention provides a method of determining clostridial toxin activity by (a) contacting with a sample a cell containing a clostridial toxin substrate that includes a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission sp... | 07/06/2010 |
| 7749514 | Activatable clostridial toxins Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids. ... | 07/06/2010 |
| 7740868 | Activatable clostridial toxins Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids. ... | 06/22/2010 |
| 7736659 | Clostridial toxin derivatives and methods for treating pain Agents for treating pain, methods for producing the agents and methods for treating pain by administration to a patient of a therapeutically effective amount of the agent. The agent can include a clostridial neurotoxin, or a component or fragment or derivative there... | 06/15/2010 |
| 7728034 | Treating neurological disorders using selective antagonists of persistent sodium current The present invention provides methods of treating neurological disorders in a mammal by administering to the mammal an effective amount of a selective persistent sodium channel antagonist that has at least 20-fold selectivity for persistent sodium current relative ... | 06/01/2010 |
| 7723480 | Leucine-based motif and clostridial neurotoxins Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, preferably the biological half-life, of the modified neurotoxin relative to an identical neurotoxin without the struct... | 05/25/2010 |
| 7723053 | High-throughput screen for identifying selective persistent sodium channels channel blockers A method for identifying a selective persistent Na+ channel blocker by measuring the ability of the blocker to reduce or inhibit a persistent Na+ current to a greater degree than a transient Na+ current. Aspects of the present method... | 05/25/2010 |
| 7718830 | Abnormal cannabidiols as agents for lowering intraocular pressure The present invention provides a method of treating glaucoma or ocular hypertension which comprises applying to the eye of a person in need thereof an amount sufficient to treat glaucoma or ocular hypertension of a compound of formula I | 05/18/2010 |
| 7718766 | Fret protease assays for botulinum serotype A/E toxins The present invention provides clostridial toxin substrates useful in assaying for the protease activity of any clostridial toxin, including botulinum toxins of all serotypes as well as tetanus toxins. A clostridial toxin substrate of the invention contains a donor ... | 05/18/2010 |
| 7709608 | Substrates useful for FRET protease assays for botulinum serotype A/E toxins The present invention provides clostridial toxin substrates useful in assaying for the protease activity of any clostridial toxin, including botulinum toxins of all serotypes as well as tetanus toxins. A clostridial toxin substrate of the invention contains a donor ... | 05/04/2010 |
| 7709228 | Activatable recombinant neurotoxins Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids. ... | 05/04/2010 |
| 7705125 | Leucine-based motif and Clostridial neurotoxins Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, preferably the biological half-life, of the modified neurotoxin relative to an identical neurotoxin without the struct... | 04/27/2010 |
| 7705124 | Leucine-based motif and clostridial neurotoxins Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, preferably the biological half-life, of the modified neurotoxin relative to an identical neurotoxin without the struct... | 04/27/2010 |
| 7705055 | Treating neurological disorders using selective antagonists of persistent sodium current The present invention provides methods of treating neurological disorders in a mammal by administering to the mammal an effective amount of a selective persistent sodium channel antagonist that has at least 20-fold selectivity for persistent sodium current relative ... | 04/27/2010 |
| 7704512 | Clostridial toxin derivatives and methods for treating pain Agents for treating pain, methods for producing the agents and methods for treating pain by administration to a patient of a therapeutically effective amount of the agent. The agent can include a clostridial neurotoxin, or a component or fragment or derivative there... | 04/27/2010 |
| 7691983 | Chimera botulinum toxin type E The present invention relates to a toxin comprising a modified light chain of a botulinum toxin type E, wherein the modified light chain comprises amino acid sequence PFVNKQFN (SEQ ID NO: 120) at the N-terminus, and amino acid sequence xExxxLL (SEQ ID NO: 112) at th... | 04/06/2010 |
| 7691974 | Leucine-based motif and clostridial neurotoxins Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, preferably the biological half-life, of the modified neurotoxin relative to an identical neurotoxin without the struct... | 04/06/2010 |
| 7691587 | Determining and reducing immunoresistance to a botulinum toxin therapy using botulinum toxin B peptides The present invention provides BoNT/B peptides, BoNT/B peptide compositions, tolerogizing compositions, immune response inducing compositions, as well as methods of determining immunoresistance to botulinum toxin therapy in an individual, methods of treating immunor... | 04/06/2010 |
| 7678550 | FRET protease assays for botulinum serotype A/E toxins The present invention provides clostridial toxin substrates useful in assaying for the protease activity of any clostridial toxin, including botulinum toxins of all serotypes as well as tetanus toxins. A clostridial toxin substrate of the invention contains a donor ... | 03/16/2010 |
| 7671177 | Leucine-based motif and clostridial neurotoxins Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, preferably the biological half-life, of the modified neurotoxin relative to an identical neurotoxin without the struct... | 03/02/2010 |
| 7670788 | Determining and reducing immunoresistance to a Botulinum toxin therapy using Botulinum toxin B peptides The present invention provides BoNT/B peptides, BoNT/B peptide compositions, tolerogizing compositions, immune response inducing compositions, as well as methods of determining immunoresistance to botulinum toxin therapy in an individual, methods of treating immunor... | 03/02/2010 |
| 7655625 | Methods of treating blepharospasm using cyclosporine components Methods of treating humans or animals afflicted with primary blepharospasm, for example, benign essential blepharospasm, or secondary blepharospasm not caused by an ocular surface disease or condition, are component to a human or animal so afflicted. ... | 02/02/2010 |
| 7655396 | Methods for detecting receptor modulator activity Disclosed herein are methods of screening compounds that modulate G-protein coupled receptors. The assays are performed at temperatures of between about 25° C. and 40° C. ... | 02/02/2010 |
| 7645570 | Botulinum toxin screening assays Methods for detecting BoNT/A activity in a sample, methods for screening molecules able to compete with BoNT/A receptor binding, methods for reducing BoNT/A activity in a human and methods of marketing a neurotoxin capable of selectively binding to FGFR3 to a govern... | 01/12/2010 |
